PDT Partners’s Collegium Pharmaceutical COLL Stock Holding History

PDT Partners’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,382	Closed	-$476K	–	524
2026 Q1	$476K	Hold	14,382	–	–	0.03%	420
2025 Q4	$666K	Hold	14,382	–	–	0.04%	384
2025 Q3	$503K	Hold	14,382	–	–	0.03%	451
2025 Q2	$425K	Buy	+14,382	New	+$410K	0.02%	545
2023 Q1	–	Sell	-25,804	Closed	-$599K	–	593
2022 Q4	$599K	Sell	25,804 -10,496	-29%	-$212K	0.1%	347
2022 Q3	$582K	Sell	36,300 -21,711	-37%	-$383K	0.09%	391
2022 Q2	$1.03M	Buy	58,011 +43,207	+292%	+$727K	0.09%	389
2022 Q1	$301K	Buy	+14,804	New	+$280K	0.03%	720
2020 Q1	–	Sell	-36,390	Closed	-$749K	–	684
2019 Q4	$749K	Sell	36,390 -7,310	-17%	-$122K	0.05%	334
2019 Q3	$502K	Sell	43,700 -11,100	-20%	-$127K	0.03%	340
2019 Q2	$721K	Buy	+54,800	New	+$733K	0.04%	278
2016 Q4	–	Sell	-23,800	Closed	-$458K	–	507
2016 Q3	$458K	Hold	23,800	–	–	0.03%	384
2016 Q2	$282K	Buy	+23,800	New	+$393K	0.02%	382

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

PDT Partners's COLL Position: Q2 2026 in Review

PDT Partners sold out of Collegium Pharmaceutical (COLL) in Q2 2026, closing a stake of 14,382 shares — an estimated $476K sold.

PDT Partners first reported a position in COLL in Q2 2016 and held it in 13 quarters. The position peaked at $1.03M in Q2 2022. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

PDT Partners reported no remaining Collegium Pharmaceutical position as of Q2 2026 after selling out during the quarter.
PDT Partners sold 14,382 Collegium Pharmaceutical shares in Q2 2026, an estimated $476K.
PDT Partners first reported a position in Collegium Pharmaceutical in Q2 2016 and held it in 13 quarters.
PDT Partners's Collegium Pharmaceutical position peaked at $1.03M in Q2 2022.
279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.